The application of oncotype DX in early-stage lymph-node-positive disease topical collection on breast cancer

Sarika Jain, William J. Gradishar*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

5 Scopus citations

Abstract

The recurrence score derived from the 21-gene Oncotype DX assay is both prognostic and predictive of adjuvant chemotherapy benefit in node-negative, estrogen-receptor-positive breast cancer patients treated with tamoxifen. This has led to a remarkable shift in the treatment paradigm, with a sizeable number of patients being able to avoid adjuvant chemotherapy. The recurrence score was then analyzed in a large retrospective study with node-positive, estrogen-receptor-positive patients, in which it demonstrated both prognostic and predictive abilities. This review introduces the clinical trials that validated the Oncotype DX assay in the node-negative population, highlights the studies evaluating the utility of the assay in node-positive patients, examines the impact of the assay results on treatment decisions, and discusses the health outcomes and health care expenditures associated with this assay.

Original languageEnglish (US)
Article number360
JournalCurrent oncology reports
Volume16
Issue number1
DOIs
StatePublished - Jan 1 2014

Keywords

  • Breast cancer
  • Chemotherapy
  • Early stage
  • Hormone therapy
  • Lymph node positive
  • Oncotype DX
  • Recurrence score

ASJC Scopus subject areas

  • Oncology

Fingerprint Dive into the research topics of 'The application of oncotype DX in early-stage lymph-node-positive disease topical collection on breast cancer'. Together they form a unique fingerprint.

Cite this